FIP1L1-PDGFRalpha in hypereosinophilic syndrome and mastocytosis

Hematol J. 2004:5 Suppl 3:S133-7. doi: 10.1038/sj.thj.6200439.
No abstract available

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / therapeutic use
  • Benzamides
  • Cell Transformation, Neoplastic / genetics
  • Enzyme Inhibitors / therapeutic use
  • Humans
  • Hypereosinophilic Syndrome / drug therapy
  • Hypereosinophilic Syndrome / enzymology
  • Hypereosinophilic Syndrome / genetics*
  • Imatinib Mesylate
  • Mastocytosis, Systemic / drug therapy
  • Mastocytosis, Systemic / enzymology
  • Mastocytosis, Systemic / genetics*
  • Mice
  • Oncogene Proteins, Fusion
  • Oncogenes
  • Piperazines / therapeutic use
  • Pyrimidines / therapeutic use
  • Radiation Chimera
  • Receptor, Platelet-Derived Growth Factor alpha / antagonists & inhibitors
  • Receptor, Platelet-Derived Growth Factor alpha / genetics
  • Receptor, Platelet-Derived Growth Factor alpha / physiology*
  • Xenograft Model Antitumor Assays
  • mRNA Cleavage and Polyadenylation Factors / antagonists & inhibitors
  • mRNA Cleavage and Polyadenylation Factors / genetics
  • mRNA Cleavage and Polyadenylation Factors / physiology*

Substances

  • Antineoplastic Agents
  • Benzamides
  • Enzyme Inhibitors
  • Oncogene Proteins, Fusion
  • Piperazines
  • Pyrimidines
  • mRNA Cleavage and Polyadenylation Factors
  • Imatinib Mesylate
  • FIP1L1-PDGFRA fusion protein, human
  • Receptor, Platelet-Derived Growth Factor alpha